William Elmquist, PharmD, PhD

Distinguished Professor, Department of Pharmaceutics

William Elmquist

Contact Info

elmqu011@umn.edu

Office Phone 612-625-0097

Fax 612-626-2125

Office Address:
9-151A Weaver-Densford Hall

Mailing Address:
University of Minnesota
College of Pharmacy
Department of Pharmaceutics
Room 9-177 WDH
308 Harvard St. SE
Minneapolis, MN 55455
USA

PharmD in Clinical Pharmacy, 1984

PhD in Pharmaceutics, University of Minnesota, 1992

BS in Pharmacy, University of Florida, 1982; BA in Zoology, University of South Florida, 1976

Research

Research Summary/Interests

  • Pharmacokinetics

Publications

  • Agarwal S., Sane R., Ohlfest J.R. and Elmquist W.F. Role of breast cancer resistance protein (ABCG2/BCRP) in the distribution of sorafenib to the brain. J. Pharmacol. Exp. Ther. Oct 15, 2010. [Epub ahead of print] PMID:20952483.
  • Agarwal S., Sane R., Gallardo J., Ohlfest J. and Elmquist W.F. Brain distribution of gefitinib is limited by p-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) mediated active efflux. J. Pharmacol. Exp. Ther. 334(1): 147-55 (2010).
  • Bungay P.M., Wang T., Yang H. and Elmquist W.F. Utilizing transmembrane convection to enhance solute sampling and delivery by microdialysis: theory and in vitro validation. Journal of Membrane Science 348(1-2): 131-149 (2010).
  • Pan G., Winter T.N., Roberts J.C., Fairbanks C.A. and Elmquist W.F. Organic cation uptake is enhanced in BCRP1-transfected MDCKII cells. Molecular Pharmaceutics 7(1): 138-145 (2010).
  • Chen Y., Agarwal S., Shaik N.M., Chen C., Yang Z. and Elmquist W.F. P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib. J. Pharmacol. Exp. Ther. 330(3): 956-63 (2009).
  • Shaik N., Giri N. and Elmquist W.F. Investigation of the micellar effect of pluronic P85 on p-glycoprotein inhibition: cell accumulation and equilibrium dialysis studies. J. Pharm. Sci. 98(11): 4170-90 (2009).
  • Giri N., Agarwal S., Shaik N., Pan G., Chen Y. and Elmquist WF. Substrate-dependent breast cancer resistance protein (Bcrp1/Abcg2)-mediated interactions: consideration of multiple binding sites in in vitro assay design. Drug Metab Dispos. 37(3): 560-70 (2009).
  • Giri N., Pan G., Shaik N., Terasaki T., Mukai C., Kitagaki S., Miyakoshi N. and Elmquist W.F. Investigation of the role of Abcg2/Bcrp1 on pharmacokinetics and CNS penetration of abacavir (ABC) and aidovudine (AZT) in the mouse. Drug Metab. Dispos. 36(8): 1476-84 (2008).
  • Shaik N., Pan G. and Elmquist W.F. Interactions of pluronic block copolymers on P-gp efflux activity: experience with HIV-1 protease inhibitors. J. Pharm. Sci. 97(12): 5421-33 (2008).
  • Shaik N., Giri N., Pan G. and Elmquist W.F. P-glycoprotein-mediated active efflux of the anti-HIV1 nucleoside abacavir limits cellular accumulation and brain distribution. Drug Metabolism and Disposition 35(11): 2076-2085 (2007).
  • Pan G., Giri N. and Elmquist W.F. Abcg2/Bcrp1 mediates the polarized transport of anti-retroviral nucleosides abacavir and zidovudine. Drug Metabolism and Disposition 35(7): 1165-1173 (2007).
  • Pan G. and Elmquist W.F. Mitoxantone permeability in MDCKII cells is influenced by active influx transport. Molecular Pharmaceutics 4(3): 475-483 (2007).
  • Spitzenberger T.J., Heilman D., Diekmann C., Batrakova E., Kabanov A.V., Gendelman H.E., Elmquist W.F. and Persidsky Y. Novel delivery system enhances efficacy of antiretroviral therapy in animal model for HIV-1 encephalitis (HIVE). J. Cerebral Blood Flow and Metab. 27(5): 1033-1042 (2007).
  • Kirstein M.N., Brundage R.C., Elmquist W.F., Remmel R.P., Marker P.H., Guire D.E. and Yee D. Characterization of an in vitro cell culture bioreactor system to evaluate anti-neoplastic drug regimens. Breast Cancer Res. Treat. 96(3): 217-225 (2006).
  • Hitzman C.J., Elmquist W.F., Wattenberg L.W. and Wiedmann T.S. Development of a respirable, sustained release microcarrier for 5-fluorouracil I : In vitro assessment of liposomes, microspheres, and lipid coated nanoparticles. J. Pharm. Sci. 95(5): 1114-1126 (2006).
  • Hitzman C.J., Elmquist W.F. and Wiedmann T.J. Development of a respirable, sustained release microcarrier for 5-fluorouracil II : In vitro and in vivo optimization of lipid coated nanoparticles. J. Pharm. Sci. 95(5): 1127-1143 (2006).
  • Hitzman C.J., Wiedmann T.S., Dai H. and Elmquist W.F. Measurement of drug release from microcarriers by microdialysis. J. Pharm. Sci. 94(7): 1456-1466 (2005).
  • Bachmeier C.J., Spitzenberger T.J., Elmquist W.F. and Miller D.W. Quantitative Assessment of HIV-1 protease inhibitors interactions with drug efflux transporters in the blood brain barrier. Pharm. Res. 22(8): 1259-1268 (2005).
  • Dai H., Chen Y. and Elmquist W.F. Distribution of the novel antifolate Pemetrexed to the brain. J. Pharmacol. Exp. Therap. 315(1): 222-229 (2005).
  • Zhang Y., Schuetz J.D., Elmquist W.F. and Miller D.W. Plasma membrane localization of multidrug resistance-associated protein (MRP) homologues in brain capillary endothelial cells. J. Pharmacol. Exp Therap. 311(2): 449-455 (2004).
  • Benjamin R.K., Hochberg F.H., Fox E., Bungay P.M., Elmquist W.F., et al. Review of microdialysis in brain tumors, from concept to application: First Annual Carolyn Frye-Halloran Symposium. Neuro-Oncology 6(1): 65-74 (2004).
  • Dai H. and Elmquist W.F. Drug transport studies using quantitative microdialysis. Methods Mol. Med. 89: 249-264 (2003).
  • Sun H., Dai H., Shaik N. and Elmquist W.F. Drug efflux transporters in the CNS. Advanced Drug Delivery Reviews 55(1): 83-105 (2003).
  • Dai H., Marbach P., Lemaire M., Hayes M. and Elmquist W.F. Distribution of STI-571 to the brain is limited by p-glycoprotein mediated efflux. J. Pharmacol. Exp. Therap. 304(3): 1085-1092 (2003).
  • Dash A.K. and Elmquist W.F. Separation methods that are capable of revealing blood-brain barrier permeability. J. Chromatography B 797(1-2): 241-254 (2003).